Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy LUND, Sweden, April 15, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration will lead to the expansion of Alligator's proprietary patient specific immunotherapy Neo-X-Prime by incorporating...
Source: finanznachrichten.de